Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talactoferrin in advanced NSCLC
NCT00707304Phase 3Completed
- Sponsor
- Agennix AG
- Start
- Nov 2008
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
A Phase 3 trial of lactoferrin in non-small cell lung cancer (NSCLC), sponsored by Agennix AG. Started Nov 2008; status: completed.
02
Drugs
lactoferrin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00707304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707304.